Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Bremelanotide vs Other Sexual Function Treatments: Mechanism Comparison

Understanding where bremelanotide fits in the therapeutic landscape requires comparing it to existing treatments across mechanism, efficacy, and safety profiles. Melanocortin Receptor Agonist MC3R/MC4R activation in CNS; modulates desire pathways Bremelanotide

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Understanding where bremelanotide fits in the therapeutic landscape requires comparing it to existing treatments across mechanism, efficacy, and safety profiles.
  • Melanocortin Receptor Agonist
  • MC3R/MC4R activation in CNS; modulates desire pathways
  • Bremelanotide (Vyleesi)
  • FSFI desire domain +0.3 vs placebo; 25% responder rate
  • Nausea (40%), flushing (20%), transient BP increase, injection site reactions
  • Only centrally-acting option for desire disorders; nausea limits tolerability; on-demand dosing
  • PDE5 Inhibitors
  • Increases cGMP in vascular smooth muscle; enhances genital blood flow
  • Sildenafil, tadalafil (off-label in women)
  • Limited evidence in women; no consistent effect on desire
  • Headache, flushing, visual disturbances
  • Targets arousal/lubrication, not desire; FDA-approved only for men; some off-label use
  • Hormone Therapy
  • Replaces or modulates estrogen/testosterone
  • Estrogen therapy, testosterone patches (off-label)
  • Variable; testosterone shows modest desire improvement in postmenopausal women
  • Estrogen: thrombosis risk, endometrial proliferation; Testosterone: virilization, unclear long-term safety
  • Addresses hormonal deficiency, not primary desire dysfunction; age and menopause status matter
  • Flibanserin (Addyi)
  • 5-HT1A agonist, 5-HT2A antagonist; modulates serotonin, dopamine, norepinephrine
  • Flibanserin
  • FSFI total score +0.3–0.4 vs placebo; 10% additional responders vs placebo
  • Dizziness, somnolence, severe interaction with alcohol
  • Daily oral dosing; CNS-acting but different receptor target; alcohol contraindication
  • The comparison reveals that no single treatment addresses all dimensions of sexual function. Bremelanotide and flibanserin both act centrally to influence desire pathways, but through entirely different receptor mechanisms. Bremelanotide via melanocortin receptors and flibanserin via serotonergic modulation. The clinical significance is that patients who don't respond to one may respond to the other, though head-to-head trials comparing the two have not been conducted. PDE5 inhibitors and hormone therapies target different aspects of sexual response (arousal, lubrication, physiological capacity) and are mechanistically irrelevant to primary desire disorders unless a vascular or hormonal deficiency is the underlying cause.
  • Here's the honest answer: the absolute efficacy of bremelanotide is modest. A 0.3-point improvement on the FSFI desire domain (which has a range of 1.2 to 6.0) and a 25% responder rate versus 17% placebo means that roughly 1 in 8 women treated will experience meaningful benefit attributable to the drug. That doesn't make it ineffective. It means sexual desire is a complex, multifactorial phenomenon that no single receptor agonist can fully address. Realistic expectations matter: bremelanotide is a tool for a specific subset of women with HSDD, not a universal solution.